To screen tau aggregation regulator, we developed a cell-based tau aggregation assay using tauC3, a caspase-cleaved form of human 0N4R tau (1–420), which is found in the brains of AD patients [27] and aggregates faster than wild-type tau in vitro [28]. This evidence concerns the gene MAPT and Alzheimer disease.